Scinai Immunotherapeutics Ltd. (SCNI)

USD 3.39

(-2.02%)

Market Cap (In USD)

2.89 Million

Revenue (In USD)

-

Net Income (In USD)

-6.5 Million

Avg. Volume

532.14 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.23-8.92
PE
-
EPS
-
Beta Value
2.463
ISIN
US09073Q2049
CUSIP
-
CIK
1611747
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Amir Reichman M.B.A., M.Sc.
Employee Count
-
Website
https://www.scinai.com
Ipo Date
2015-05-11
Details
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.